56 completed. 56 Phase 2, 19 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 56 | Completed 56 |
| Phase 1 | 19 | Completed 19 |
| Phase 3 | 1 | Completed 1 |
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 38 | 2017-11-14 | 2026-10-28 |
| A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Brentuximab vedotin - T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | Deepa Jagadeesh | 23 | 2016-06-17 | 2025-11-21 |
| Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 1 / Phase 2 | Completed | University of Nebraska | 54 | 2015-09-28 | 2023-12-13 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma romidepsin, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Northwestern University | 30 | 2015-06-11 | 2026-06-12 |
| Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Enasidenib - Solid Tumor, Glioma | Phase 1 / Phase 2 | Completed | Celgene | 21 | 2014-12-08 | 2021-02-23 |
| Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas Ro-CHOEP-21 (PHASE I), Ro-CHOEP-21 (PHASE II) - Peripheral T-cell Lymphomas (PTCL), PTCL-NOS | Phase 1 / Phase 2 | Completed | Fondazione Italiana Linfomi - ETS | 89 | 2014-09-01 | 2026-08-19 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2011-10-01 | 2016-03-10 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma prednisone, cyclophosphamide, etoposide - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | University of Nebraska | 34 | 2011-07-06 | 2023-09-22 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma panobinostat, laboratory biomarker analysis, western blotting - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Mayo Clinic | 41 | 2011-01-17 | 2022-05-24 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma everolimus, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 58 | 2011-01-10 | 2020-10-22 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma bendamustine hydrochloride, dexamethasone, filgrastim - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | University of Washington | 43 | 2010-08-01 | 2017-05-24 |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas RAD001 (Everolimus) - Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 46 | 2010-07-01 | 2015-03-03 |
| Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma panobinostat and bortezomib - Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | Singapore General Hospital | 25 | 2009-11-01 | 2014-06-27 |
Showing 20 of 56. Sign in to see all of them.
Lymphoma, Large-Cell, Anaplastic (51) · Lymphoma, Large B-Cell, Diffuse (40) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (40) · Lymphoma, Follicular (38) · Lymphoma, Mantle-Cell (37) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (37) · Burkitt Lymphoma (36) · Lymphoma, B-Cell, Marginal Zone (36) · Lymphoma, Non-Hodgkin (36) · Lymphoma, T-Cell, Cutaneous (36) · Leukemia, Lymphocytic, Chronic, B-Cell (35) · Waldenstrom Macroglobulinemia (35) · Hodgkin Disease (33) · Lymphoma, Large-Cell, Immunoblastic (33)
Hemic and Lymphatic Diseases (56) · Immune System Diseases (56) · Immunoproliferative Disorders (56) · Lymphadenopathy (56) · Lymphatic Diseases (56) · Neoplasms by Histologic Type (56) · Neoplasms (54) · Lymphoproliferative Disorders (52) · Hematologic Diseases (44) · Lymphoma, T-Cell (44) · Leukemia, Lymphoid (43) · Lymphoma, B-Cell (41) · Disease Attributes (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38)
Cyclophosphamide (16) · fludarabine phosphate (12) · Peripheral Blood Stem Cell Transplantation (11) · Whole-Body Irradiation (10) · Etoposide (7) · Mycophenolic Acid (7) · Vincristine (7) · Cyclosporine (6) · Prednisone (6) · Busulfan (5) · Doxorubicin (5) · Tacrolimus (5) · Antilymphocyte Serum (4) · Carboplatin (4) · Everolimus (4)
Fred Hutchinson Cancer Center (9) · National Cancer Institute (NCI) (7) · Mayo Clinic (5) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Memorial Sloan Kettering Cancer Center (3) · Case Comprehensive Cancer Center (2) · M.D. Anderson Cancer Center (2) · Northwestern University (2) · Roswell Park Cancer Institute (2) · University of Nebraska (2) · University of Washington (2) · Acrotech Biopharma Inc. (1) · Asan Medical Center (1) · BeiGene (1) · Cancer Treatment Centers of America (1)
United States (48) · Italy (8) · France (5) · Belgium (3) · South Korea (3) · Canada (2) · Egypt (2) · Germany (2) · Netherlands (2) · Switzerland (2) · China (1) · Croatia (1) · Malaysia (1) · Portugal (1) · Singapore (1)
Brenda Sandmaier (3) · Ajay Gopal (2) · David Maloney (2) · Anas Younes (1) · Asad Bashey, MD, PhD (1) · Charles L. Loprinzi, M.D. (1) · Claudio Anasetti, MD (1) · Claudio Viscoli, MD (1) · Craig Reeder, M.D. (1) · Darryl Tan, MBBS MMED (1) · David J. Straus, MD (1) · Deepa Jagadeesh, MD, MPH (1) · Elizabeth C. Dees, MD (1) · Esperanza B. Papadopoulos, MD (1)
PMID 32499241, PMID 18327587, PMID 19170225, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20942843, PMID 21135857, PMID 25921059, PMID 26077240, PMID 26213141, PMID 26688485, PMID 26764356, PMID 28314788, PMID 37276067, PMID 37327113, PMID 39821757
P30CA015704 (6), P01CA018029 (3), P30CA015083 (3), P01CA078902 (2), P30CA008748 (2), P30CA036727 (2), 2014 (1), 2017 (1), N01CM00039 (1), N01CM62202 (1), P30CA016672 (1), P30CA033572 (1), P30CA043703 (1), P30CA060553 (1), U01CA069856 (1)